Named on 3 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2026-06-10 to ~ 2026-10-10
ROUNDS
3
joined, none as lead
ROUNDS JOINED · USD
$440M
across 3 rounds
CO-INVESTORS
36
named beside it
Named on 3 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2026-06-10 to ~ 2026-10-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Soufflé Therapeutics A leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives | Series B Verified against 1 of 29 sources | $135M | ~ 2026-10-10 | [ PART ] |
Celea Therapeutics Celeatx offers investigational medications, particularly deupirfenidone, for the treatment of idiopathic pulmonary fibrosis (IPF). | Funding round Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $180M | 2026-07-02 | [ PART ] |
SonoThera SonoThera develops innovative ultrasound-mediated nonviral genetic therapies targeting various medical conditions. | Series B Verified against 1 of 7 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-06-10 | [ PART ] |